According to research led by Prof. Varut Lohsiriwat, Professor of Surgery, Division of General Surgery (Section of Colorectal Surgery) of Siriraj Hospital, at Mahidol University, CRC is the third most common cancer in Thailand, accounting for 11% of the cancer burden. It is the only malignancy with an increased incidence in both genders in the country.
By 2040, the burden of CRC is projected to increase to 3.2 million new cases and 1.6 million deaths per year representing a 66% and 71% rise in new cases and deaths respectively relative to 2020.
To better address the global burden of CRC and reduce its impact, BGI Genomics has launched the second edition of its global CRC awareness report, covering 1,938 respondents from Brazil (306), China (367), Poland (300), Saudi Arabia (300), Thailand (362), and Uruguay (303):
Preference for Fecal Testing Over Colonoscopy: Although colonoscopies are more recognized (33.4%), fecal tests at healthcare facilities are preferred (31.8%), reflecting a trend towards non-invasive methods. Professor Varut Lohsiriwat suggest "Doctors usually will explain the pros and cons for the patient in 3 to 5 mins about different screening method. But in the end, it's the patients that makes the decision and the best screening method is the one that accepted by the patients".
Cost as the Determinant in Screening Choices: Cost plays a crucial role in individuals' decisions regarding CRC screening in Thailand. Thailand (24.5%) and Poland (20.6%) indicate the most concern about costs, with 88.2% of Thai preferring either moderately priced options with good accuracy or inexpensive options with average accuracy.
Medical Advice and Family History Drive CRC Screening: Given that doctor's recommendations (29.1%) are the biggest single factor that makes Thai individuals more likely to undergo screening for CRC without any symptoms. Additionally, Thai with a family history of CRC are more proactive in screening (62.8%), compared to the general population (33.4%). This points to the critical role of healthcare professionals and familial awareness in encouraging screening.
For more region-level comparisons, access the full BGI Genomics 2024 State of CRC Awareness Report.
All data involved in this report come from the results of an online survey project conducted by BGI Genomics. It only surveys awareness related to colorectal cancer and does not involve personally identifiable data.
About BGI Genomics and COLOTECT
BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.
COLOTECT is a non-invasive fecal DNA test developed by BGI Genomics for detecting CRC and precancerous lesions. It uses multiplex methylation-specific PCR (MSP) technology to trace abnormal DNA-methylation biomarkers in CRC from stool samples. It has 88% CRC sensitivity, and for early detection, its sensitivity for advanced adenoma is 46%, which are both superior to conventional fecal tests.
